In fact, in a murine KRAS-mutant colorectal cancer model, the MEK inhibitor selumetinib seemed to attenuate anti-CTLA-4-mediated T-cell-activation and infiltration into tumors without abrogating these effects. This evidence concerns the gene KRAS and colorectal cancer.